Detections of the regulated noxious parasitic weed branched broomrape (Phelipanche ramosa) in California tomato fields have led to interest in eradication, sanitation, and management practices. Researchers in Israel developed a decision-support system and herbicide treatment regime for management of Egyptian broomrape (P. aegyptiaca) in tomato. Research was conducted in 2019 and 2020 to evaluate whether similar treatments could be used to manage branched broomrape in California processing tomatoes and to provide registration support data for the herbicide use pattern. Treatment programs based on preplant incorporated (PPI) sulfosulfuron and chemigated imazapic were evaluated in 2019 and 2020 to determine safety on the processing tomato crop and on common rotational crops. Three single-season tomato safety experiments were conducted and a single rotational crop study was conducted in which a tomato crop received herbicide treatments in 2019 and several common rotational crops were planted and evaluated in 2020 in a site without branched broomrape. In 2020, an efficacy study was conducted in a commercial tomato field known to be infested with branched broomrape to evaluate the efficacy of PPI sulfosulfuron and chemigated imazapic, imazapyr, imazethapyr, and imazamox. After two field seasons, sulfosulfuron and imazapic appeared to have reasonable crop safety on tomato in California; however, rotational crop restrictions will need to be considered if sulfosulfuron is used to manage branched broomrape. In the efficacy study, there was a trend in which the sulfosulfuron and imidazolinone treatments had fewer broomrape shoots per plot than the grower standard treatments, however, none were fully effective and there were no significant differences among the various sulfosulfuron and imidazolinone treatment combinations. Additional research is needed to optimize the treatment timing for management of branched broomrape in this cropping system. Because of registration barriers with imazapic in the California market, future research will focus on treatment combinations of PPI sulfosulfuron and chemigated imazamox rather than imazapic.